Oberhoff 1998.

Methods	randomized controlled trial, not placebo‐controlled
Participants	n = 227, ovarian, breast, lung, genitourinary, gastrointestinal, other cancer; concomitant treatment: chemotherapy
Interventions	drug = Epoetin beta dose = 5000 IU sc 7x per week hb‐target = 11‐14 g/dL planned ESA duration = 12 weeks
Outcomes	Primary: transfusion ; secondary: Hb response, safety
Notes	study number = 45434
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Unclear risk	no description
Allocation concealment?	Low risk	central randomization